Horton, Lodge Published in Reuters Westlaw IP About Themes in Public Comments Related to AI Patent Policy
21 December 2020
Matthew Horton and Alexandra Leigh Lodge published the article, “Notable Themes in Public Comments Submitted to the USPTO Related to AI Patent Policy” in Reuters Westlaw IP. The article looks at four themes that stood out among the comments received related to the USPTO’s August 2019 “Request for Comments on Patenting Artificial Intelligence Inventions.”
“A major takeaway is that the patent community generally feels that U.S. patent law is structured to handle AI inventions, though the report also highlighted concerns for ongoing or future evaluation,” Horton and Lodge wrote.
Themes that Horton and Lodge highlight include:
- Existing U.S. patent law is equipped for AI technology
- “Narrow AI” and “Artificial General Intelligence” (AGI) are two categories of AI that should be considered
- AI’s effect on the definition of a “Person of Ordinary Skill in the Art”
- AI’s effect on prior art
Read the full article here.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”